摘要
目的:采用Meta分析方法评价复方苦参注射液辅助肝动脉化疗栓塞(TACE)治疗肝癌的临床疗效及安全性。方法:通过计算机检索Pub Med、the Cochrane Library、Embase、中国期刊全文数据库(CNKI)、中国生物医学文献服务系统(Sino Med)、中文科技期刊数据库(VIP)、万方数据库(Wanfang)中有关复方苦参注射液联合TACE治疗肝癌的随机对照试验,检索时间从数据库建库至2016年10月。由两位研究者独立对纳入文献进行偏倚风险评价,提取资料并通过RevMan 5.3软件进行数据分析。结果:共纳入随机对照试验11项,累计患者875例。Meta分析结果显示:在TACE治疗的基础上,联用复方苦参注射液不仅可以提高肝癌患者的临床总有效率(RR=1.35,95%CI:1.18~1.53,P<0.000 01),改善患者生存质量(RR=1.28,95%CI:1.10~1.47,P=0.001),而且有助于缓解化疗药物产生的不良反应。结论:现有临床证据表明在TACE治疗基础上联用复方苦参注射液对肝癌有一定的辅助治疗作用。但本研究结论尚需更多设计良好、严格执行的大样本随机双盲对照试验加以证实。
Objective：To systematically evaluate the clinical effectiveness and safety of compound Kushen injection combined with transcatheter hepatic arterial chemoembolization （TACE） chemotherapy in the treatment of liver carcinoma. Methods：Randomized controlled trials （RCTs） regarding compound Kushen injection treating liver carcinoma were searched in PubMed, the Cochrane library, Embase, CNKI, SinoMed, VIP, and Wanfang databases from establishment to October 2016. Two researchers independently identified and evaluated the methodological quality of the included RCTs, then the data were extracted and Meta-analyzed by RevMan 5.3 software. Results：A total of 11 RCTs involving 875 participants were included. In the Meta-analysis, compound Kushen injection combined with TACE chemotherapy can be better than TACE chemotherapy regimen alone in the treatment of liver carcinoma in respect of improvement in the total effective rate （RR = 1.35, 95% CI： 1.18-1.53, P 〈0.000 01）, improvement in life quality （RR =1.28, 95% CI： 1.10-1.47, P=0.001）. In addition, compound Kushen injection can reduce the incidence rate of adverse reactions. Conclusion： Thus, our study showed that compound Kushen injection combined with TACE chemotherapy regimen is beneficial in the treatment of liver carcinoma, while our conclusion should be confirmed by more well-designed and large-scale RCTs.
出处
《药物流行病学杂志》
CAS
2017年第11期745-750,共6页
Chinese Journal of Pharmacoepidemiology
基金
国家自然科学基金项目(编号:81473547
81673829)
关键词
复方苦参注射液
肝癌
随机对照试验
META分析
Compound Kushen injection
Liver Carcinoma
Randomized controlled trial
Meta-analysis
